A randomized, double blind, comparative study of STATUS D3 (vitamin D3) versus placebo in patients with lung cancer to prevent relapse after operatio
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000001869
- Lead Sponsor
- Jikei University School of Medicine
- Brief Summary
The 5-year RFS of the vitamin D and placebo groups was 65% and 57%, respectively (HR, 1.15; 95%CI, 0.64 to 2.05; P=0.64). The 5-year OS of the vitamin D and placebo groups was 76% and 78%, respectively (HR, 1.22; 95%CI, 0.54 to 2.79; P=0.63).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 155
Inclusion Criteria
Not provided
Exclusion Criteria
1. Already taking vitamin D supplement or 1,25 vitamin D 2. History of kidney stone 3. Other difficulties judged by the surgeon in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method